Compare DexCom, Inc. (DXCM) vs International Business Machines Corp (IBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs International Business Machines Corp — how do they compare? DexCom, Inc. trades at $89.65 (market cap $33.79B), while International Business Machines Corp trades at $233.98 (market cap $224.62B). The key difference: International Business Machines Corp is far larger — about 6.6× DexCom, Inc.'s market cap, and International Business Machines Corp pays a 2.84% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | IBM | |
|---|---|---|
Market Cap | $33.79B | $224.62B |
Sector | Health | Technology |
52-Week High | $89.53 | $329.23 |
52-Week Low | $54.84 | $205.77 |
Enterprise Value | $33.24B | $281.76B |
Volume | — | 4,481,527 |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
IBM trades at $236.31, down 0.41% today, with a mixed technical picture showing bearish moving averages but bullish overall signals. Recent earnings beat expectations in Q4 2025 and Q1 2026, with Q2 2026 meeting estimates, while revenue grew to $67.54 billion in 2025. The company secured a $240 million AI deal with Together AI, boosting sentiment despite ongoing securities fraud investigations.
Outlook: IBM's strong profitability and AI growth present upside potential, but legal risks and high valuation ratios pose challenges. The consensus price target of $257.38 suggests moderate growth, supported by institutional buy ratings, though investors should monitor legal developments and competitive pressures in the tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →
